A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-positive/HER2-negative, Early Stage Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Taselisib (Primary) ; Letrozole
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms LORELEI
- Sponsors Genentech
- 07 Jun 2017 Biomarkers information updated
- 09 May 2017 Status changed from active, no longer recruiting to completed.
- 03 May 2017 This trial has been completed in Germany (end date: 13 Mar 2017).